753 related articles for article (PubMed ID: 23511301)
1. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies.
Wohl DA; Zeng D; Stewart P; Glomb N; Alcorn T; Jones S; Handy J; Fiscus S; Weinberg A; Gowda D; van der Horst C
J Acquir Immune Defic Syndr; 2005 Apr; 38(5):538-44. PubMed ID: 15793363
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome.
Sungkanuparph S; Chakriyanuyok T; Butthum B
J Infect; 2008 Jan; 56(1):40-3. PubMed ID: 18037166
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus viremia in dried blood spots is associated with an increased risk of death in HIV-infected patients: a cohort study from rural Tanzania.
Brantsæter AB; Johannessen A; Holberg-Petersen M; Sandvik L; Naman E; Kivuyo SL; Rollag H; Bruun JN; Kvale D
Int J Infect Dis; 2012 Dec; 16(12):e879-85. PubMed ID: 23031419
[TBL] [Abstract][Full Text] [Related]
6. Correlates of change in cytomegalovirus viremia in patients with advanced human immunodeficiency virus infection who require transfusion.
Para MF; Kalish LA; Collier AC; Murphy EL; Drew WL;
J Infect Dis; 2001 Jun; 183(11):1673-7. PubMed ID: 11343218
[TBL] [Abstract][Full Text] [Related]
7. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
8. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.
Weinberg A; Tierney C; Kendall MA; Bosch RJ; Patterson-Bartlett J; Erice A; Hirsch MS; Polsky B;
J Infect Dis; 2006 Feb; 193(4):488-93. PubMed ID: 16425127
[TBL] [Abstract][Full Text] [Related]
10. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
[TBL] [Abstract][Full Text] [Related]
11. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
12. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.
O'Sullivan CE; Drew WL; McMullen DJ; Miner R; Lee JY; Kaslow RA; Lazar JG; Saag MS
J Infect Dis; 1999 Sep; 180(3):847-9. PubMed ID: 10438377
[TBL] [Abstract][Full Text] [Related]
13. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
[TBL] [Abstract][Full Text] [Related]
14. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
15. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
16. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
[TBL] [Abstract][Full Text] [Related]
17. [Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy].
Reus S; Portilla J; Gimeno A; Sánchez-Payá J; García-Henarejos JA; Martínez-Madrid O; Usó J; Roca B; Galindo MJ; López-Aldeguer J
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):142-9. PubMed ID: 14987534
[TBL] [Abstract][Full Text] [Related]
18. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
Mattioni S; Pavie J; Porcher R; Scieux C; Denis B; De Castro N; Simon F; Molina JM
Int J STD AIDS; 2015 Apr; 26(5):306-12. PubMed ID: 24845948
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
Erice A; Tierney C; Hirsch M; Caliendo AM; Weinberg A; Kendall MA; Polsky B;
Clin Infect Dis; 2003 Aug; 37(4):567-78. PubMed ID: 12905142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
